Stockreport

NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy With Durable, Complete Response Data and 78% Disease Control in ...

NANTKWEST  (NK) 
Last nantkwest earnings: 3/25 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
PDF World’s first combination of off-the-shelf NK with checkpoint inhibitor plus antigen simulation via adenovirus to induce immune system activationOngoing durable complete [Read more]